Stocks
Editas Medicine Financial Statements (EDIT) |
||||||||||
| Editas Medicinesmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2020 | 26.02.2021 | 24.02.2022 | 22.02.2023 | 28.02.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 20.5 | 90.7 | 25.5 | 19.7 | 78.1 | 69.4 | |||
| Operating Income, bln rub | -140.9 | -134.8 | -193.1 | -226.0 | -169.2 | -180.1 | ||||
| EBITDA, bln rub | ? | -141.1 | -134.8 | -193.1 | -226.0 | -163.1 | -177.2 | |||
| Net profit, bln rub | ? | -123.5 | -109.4 | -185.1 | -204.4 | -153.2 | -166.1 | |||
| OCF, bln rub | ? | -40.7 | -179.8 | -163.8 | -177.3 | -132.2 | -146.3 | |||
| CAPEX, bln rub | ? | 6.17 | 7.16 | 7.98 | 4.12 | 4.72 | 4.75 | |||
| FCF, bln rub | ? | -46.8 | -187.0 | -171.8 | -181.5 | -136.9 | -151.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 161.5 | 225.6 | 218.7 | 245.7 | 241.2 | 251.7 | ||||
| Cost of production, bln rub | 96.9 | 158.0 | 5.05 | 6.34 | 6.06 | 5.93 | ||||
| R&D, bln rub | 96.9 | 158.0 | 142.5 | 175.0 | 171.6 | 150.6 | ||||
| Interest expenses, bln rub | 7.31 | 0.000 | 0.000 | 4.23 | 0.000 | 3.47 | ||||
| Assets, bln rub | 508.9 | 572.6 | 677.5 | 514.3 | 499.2 | 440.3 | ||||
| Net Assets, bln rub | ? | 262.4 | 393.6 | 553.6 | 360.7 | 349.1 | 294.4 | |||
| Debt, bln rub | 29.1 | 26.1 | 26.4 | 43.9 | 36.5 | 34.1 | ||||
| Cash, bln rub | 457.1 | 511.8 | 619.9 | 437.4 | 323.1 | 296.2 | ||||
| Net debt, bln rub | -428.1 | -485.6 | -593.5 | -393.4 | -286.6 | -262.0 | ||||
| Ordinary share price, rub | 29.6 | 70.1 | 26.6 | 8.87 | 10.1 | 7.04 | ||||
| Number of ordinary shares, mln | 50.0 | 58.6 | 67.6 | 68.7 | 76.0 | 81.9 | ||||
| Market cap, bln rub | 1 480 | 4 109 | 1 795 | 609 | 770 | 577 | ||||
| EV, bln rub | ? | 1 052 | 3 623 | 1 202 | 216 | 483 | 315 | |||
| Book value, bln rub | 262 | 394 | 554 | 361 | 349 | 294 | ||||
| EPS, rub | ? | -2.47 | -1.87 | -2.74 | -2.98 | -2.02 | -2.03 | |||
| FCF/share, rub | -0.94 | -3.19 | -2.54 | -2.64 | -1.80 | -1.84 | ||||
| BV/share, rub | 5.25 | 6.72 | 8.19 | 5.25 | 4.60 | 3.59 | ||||
| EBITDA margin, % | ? | -687.1% | -148.6% | -756.1% | -1 146% | -208.8% | -255.3% | |||
| Net margin, % | ? | -601.4% | -120.6% | -724.7% | -1 037% | -196.1% | -239.4% | |||
| FCF yield, % | ? | -3.16% | -4.55% | -9.57% | -29.8% | -17.8% | -26.2% | |||
| ROE, % | ? | -47.0% | -27.8% | -33.4% | -56.7% | -43.9% | -56.4% | |||
| ROA, % | ? | -24.3% | -19.1% | -27.3% | -39.7% | -30.7% | -37.7% | |||
| P/E | ? | -12.0 | -37.6 | -9.70 | -2.98 | -5.02 | -3.47 | |||
| P/FCF | -31.6 | -22.0 | -10.5 | -3.36 | -5.62 | -3.82 | ||||
| P/S | ? | 72.1 | 45.3 | 70.3 | 30.9 | 9.85 | 8.31 | |||
| P/BV | ? | 5.64 | 10.4 | 3.24 | 1.69 | 2.20 | 1.96 | |||
| EV/EBITDA | ? | -7.46 | -26.9 | -6.22 | -0.95 | -2.96 | -1.78 | |||
| Debt/EBITDA | 3.03 | 3.60 | 3.07 | 1.74 | 1.76 | 1.48 | ||||
| R&D/CAPEX, % | 1 571% | 2 206% | 1 786% | 4 249% | 3 636% | 3 170% | ||||
| CAPEX/Revenue, % | 30.0% | 7.89% | 31.2% | 20.9% | 6.04% | 6.84% | ||||
| Editas Medicine shareholders | ||||||||||
